newsfilter
← Latest News
Business Wire·

Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food